bioRxiv · 10.64898/2025.12.20.694502
Transcriptome-wide mapping reveals an RNA-dependent mechanism of platinum cancer drugs.
Abstract
Off-target interactions frequently compromise the clinical utility of anticancer agents by driving dose-limiting toxicity and therapeutic resistance. Although RNA has been predicted to be an off-target for numerous FDA-approved drugs, the extent and functional significance of RNA off-targeting among anticancer small molecules remain poorly understood. Using a systematic drug-binding screen, we identified cisplatin, a frontline chemotherapeutic that acts canonically through DNA adduct formation, as a prominent RNA binder. We employed cisplatin as a model compound to characterize the mechanistic basis and functional impact of RNA-small molecule off-targeting. To map transcriptome-wide cisplatin-RNA interactions, we developed PlatRNA-seq, a click-chemistry-enabled RNA-binding profiling platform. Genomic and functional analyses reveal that cisplatin preferentially accumulates at RNA G-quadruplex (rG4) structures near 5' transcript ends, inducing R-loop formation. Critically, we demonstrate that cisplatin cytotoxicity is partially mediated through RNA binding, revealing a noncanonical mechanism of action. Collectively, these findings illustrate the functional consequences of RNA-small-molecule off-targeting and provide a generalizable framework for investigating small-molecule-RNA interactions, opening new avenues for therapeutic innovation.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Nair, S. J., Krishnaraj, A., Wei, X., Thakral, R., Guo, W., Subramanian, S. B., Zhang, X., Alley, K. R., Feng, A., Hoy, A., Kung, D., Tiwari, P. B., Uren, A., Maillard, R., DeRose, V. J.. 2025-12-23. Transcriptome-wide mapping reveals an RNA-dependent mechanism of platinum cancer drugs.. https://doi.org/10.64898/2025.12.20.694502
Cite the original work for its findings. Save a collection to share your selection of sources.